Lung Cancer Clinical Trials & Research at Providence Medical Group

The two main types of lung cancer are non-small cell lung cancer and small cell lung cancer. The types are based on the way the cells look under a microscope. Non-small cell lung cancer is much more common than small cell lung cancer. Tobacco smoking is the most common cause of lung cancer.

Providence Medical Group is currently enrolling patients for the following lung cancer clinical trials:

Non-Small Cell Lung Cancer
Small Cell Lung Cancer


Non-Small Cell Lung Cancer

A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Treatment agent: MRTX849 + pembrolizumab
PI: Manasa Vulchi, MD
Study Coordinator: Tracy Foster
Resources and Links: clinicaltrials.gov NCT No: NCT04613596
Sponsor: Mirati Therapeutics, Inc.


Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7)

Treatment agent: Zimberelimab with or without domvanalimab and/or etrumadenant
PI: Ian Anderson, MD
Study Coordinator: Camille Shaffer
Resources and Links: clinicaltrials.gov NCT No: NCT04262856
Sponsor: Arcus Biosciences, Inc.


Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

Treatment agent: Pembrolizumab + chemotherapy/olaparib OR chemotherapy + durvalumab
PI: Ian Anderson, MD
Study Coordinator: Tracy
Resources and Links: clinicaltrials.gov NCT No: NCT04380636
Sponsor: Merck Sharp & Dohme Corp.


A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (MeRmaiD-1)

Treatment agent: Durvalumab + chemotherapy
PI: Ian Anderson, MD
Study Coordinator: Tracy
Resources and Links: clinicaltrials.gov NCT No: NCT04385368
Sponsor: AstraZeneca


A Phase III, Open-label, Randomized Study of Osimertinib with or without Platinum Plus Pemetrexed Chemotherapy, as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA2)

Treatment agent: Osimertinib with or without platinum-based chemotherapy
PI: Ian Anderson, MD
Study Coordinator: Tracy
Resources and Links: clinicaltrials.gov NCT No: NCT04035486
Sponsor: AstraZeneca


Phase 2 Platform Study in Patients with advanced non-small lung cancer who progressed on First Line Osimertinib therapy (ORCHARD)

Treatment agent: Osimertinib
PI: Ian Anderson, MD
Study Coordinator: Tracy
Resources and Links: clinicaltrials.gov NCT No: NCT03944772


A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy Versus Placebo with Pembrolizumab and Chemotherapy in First-Line, Metastic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (KEAPSAKE CX-839-014)

Treatment agent: Telaglenastat/ placebo + SOC
PI: Ian Anderson, MD
Study Coordinator: Teresa
Resources and Links: clinicaltrials.gov No: NCT04265534


Small Cell Lung Cancer

Study of Durvalumab + Tremelimuab, Durvalumab, and Placebo in Limited Stage Small- Cell Lung Cancer in Patients who Have Not progressed following concurrent chemoradiation therapy (ADRIATIC)

Treatment: Durvalumab + Tremelimuab, Durvalumab, and Placebo
PI: Ian Anderson, MD
Study Coordinator: Tracy
Resources and Links: clinicaltrials.gov NCT No: NCT03703297


Seer-020201 (Pulmonary Nodules)

Treatment: Durvalumab + Tremelimuab, Durvalumab, and Placebo
PI: Manasa Vulchi, MD
Study Coordinator: Melissa​
NCT – NA

Our Providers

Our Locations